Abzyme Therapeutics Llc

CAGE Code: 62ES6

NCAGE Code: 62ES6

Status: Discontinued

Type: Commercial Supplier

Dun & Bradstreet (DUNS): 962964990

Summary

Abzyme Therapeutics Llc is a Discontinued Commercial Supplier with the Cage Code 62ES6 and is tracked by Dun & Bradstreet under DUNS Number 962964990..

Address

321 Jones Blvd
Ste 300
Pottstown PA 19464-3468
United States

Points of Contact

No Points of Contact...

Related Information

Associated CAGE Codes People who viewed this 'CAGE Code' also viewed...

CAGE Code FAQ Frequently Asked Questions (FAQ) for CAGE 62ES6

What is CAGE Code 62ES6?
62ES6 is the unique identifier used by NATO Organizations to reference the physical entity known as Abzyme Therapeutics Llc located at 321 Jones Blvd, Ste 300, Pottstown PA 19464-3468, United States.
Who is CAGE Code 62ES6?
62ES6 refers to Abzyme Therapeutics Llc located at 321 Jones Blvd, Ste 300, Pottstown PA 19464-3468, United States.
Where is CAGE Code 62ES6 Located?
CAGE Code 62ES6 is located in Pottstown, PA, USA.

Contracting History for CAGE 62ES6 Contracting History for CAGE 62ES6 Most Recent 25 Records

W911QY18C0004
Option Year - 2
17 Jun 2020
W6qk Acc-Apg Natick
Department Of Defense (Dod)
$999,998.10
75N91018C00031
Igf::Ot::Igf Project Title: Monoclonal Antibodies To Rna-Modifications
6 Nov 2018
Nih Nci
Department Of Health And Human Services (Hhs)
$299,999.00
75N93019C00009
The Objective Of This Contract Is To Develop Camelid Vhhs That Are Capable Of Significantly (At Least 5-Fold Improvement) Enhancing Gp120 Expression In Mammalian Cells And Applicable For Rapid And Scalable Gp120 Protein Purification.
11 May 2020
National Institutes Of Health Niaid
Department Of Health And Human Services (Hhs)
$299,815.00
75N93019C00009
The Objective Of This Contract Is To Develop Camelid Vhhs That Are Capable Of Significantly (At Least 5-Fold Improvement)Enhancing Gp120 Expression In Mammalian Cells And Applicable For Rapid And Scalable Gp120 Protein Purification.
29 May 2019
National Institutes Of Health Niaid
Department Of Health And Human Services (Hhs)
$299,815.00
W911QY18C0004
Cdrl B002 - Monthly Status Reports Yr 1
31 Jan 2019
W6qk Acc-Apg Natick
Department Of Defense (Dod)
$999,998.10
W911QY18C0004
Igf::Ot::Igf R&D Exempt
14 Nov 2017
W6qk Acc-Apg Natick
Department Of Defense (Dod)
$999,998.10
W911QY16P0229
Igf::Ot::Igf
10 Aug 2017
W6qk Acc-Apg Natick
Department Of Defense (Dod)
$149,656.59
75N91018C00031
Igf::Ot::Igf Project Title: Monoclonal Antibodies To Rna-Modifications
12 Jun 2019
Nih Nci
Department Of Health And Human Services (Hhs)
$299,999.00
W911QY18C0004
Option Year - 2
27 Feb 2019
W6qk Acc-Apg Natick
Department Of Defense (Dod)
$999,998.10
75N91018C00031
Igf::Ot::Igf Monoclonal Antibodies To Rna-Modifications (Moonshot)
5 Sep 2018
Nih Nci
Department Of Health And Human Services (Hhs)
$299,999.00
W911QY18C0004
Option Year - 2
10 Dec 2019
W6qk Acc-Apg Natick
Department Of Defense (Dod)
$999,998.10